
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
Aug 24, 2026 06:16 am UTC| Business Health
Hanmi Pharm shares surged 30% on Monday after the South Korean pharmaceutical company signed an exclusive licensing agreement with Genentech, a member of the Roche Group, for its experimental obesity drug HM17321. Under...

Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
Aug 19, 2026 21:23 pm UTC| Business Health
Moderna Inc. short sellers suffered an estimated $4.8 billion in mark-to-market losses on Wednesday as the biotech companys shares more than doubled following encouraging results from a late-stage cancer therapy trial....

AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Aug 17, 2026 08:44 am UTC| Business Health
AstraZeneca has discontinued a late-stage clinical trial evaluating volrustomig combined with chemotherapy for patients with metastatic non-small cell lung cancer (NSCLC), dealing another setback to the pharmaceutical...

Trump Signs Order to Cut Routine Childhood Vaccines
Aug 12, 2026 04:08 am UTC| Politics Governance Health
President Donald Trump has signed an executive order seeking to reduce the number of routine childhood vaccinations recommended in the United States and directing the Justice Department to challenge certain state vaccine...

Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
Aug 11, 2026 01:13 am UTC| Business Health
Hims Hers Health shares dropped more than 6% in after-hours trading after the telehealth company reported a wider-than-expected second-quarter loss, as rising costs tied to branded GLP-1 weight-loss drugs pressured...

Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Aug 06, 2026 04:41 am UTC| Business Health
Moderna (NASDAQ: MRNA) has received approval from the U.S. Food and Drug Administration (FDA) for its mRNA-based influenza vaccine, mFLUSIVA, for adults aged 50 and older. The approval marks a significant milestone for the...

Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Aug 05, 2026 08:59 am UTC| Business Health
Novo Nordisk (CSE: NOVOb, NYSE: NVO) raised its full-year 2025 guidance after stronger-than-expected demand for its blockbuster weight-loss drugs helped improve its earnings outlook. The Danish pharmaceutical company now...